NaPro BioTherapeutics to Present at the Wells Fargo Securities Health Care Conference
23 March 2004 - 4:01AM
PR Newswire (US)
NaPro BioTherapeutics to Present at the Wells Fargo Securities
Health Care Conference BOULDER, Colo., March 22
/PRNewswire-FirstCall/ -- NaPro BioTherapeutics, Inc. today
announced that Leonard Shaykin, Chairman and Chief Executive
Officer of NaPro, will present an overview of the Company's
progress and strategy at the Wells Fargo Securities Health Care
"Fireside Chats" Conference on Wednesday, March 24, 2004 at 3:15 PM
Eastern Time at the St. Regis Hotel in New York City. Wells Fargo
will provide a live audio webcast of the presentation, which can be
accessed through NaPro's website at http://www.naprobio.com/. A
replay of the webcast will be available for 90 days. About NaPro
BioTherapeutics NaPro BioTherapeutics, Inc., is a life science
company focused on the development of therapies for the treatment
of cancer and hereditary disease. Forward Looking Statements The
statements in the webcast presentation that are not historical
facts are forward-looking statements that represent management's
beliefs and assumptions as of the date of the webcast presentation,
based on currently available information. Forward-looking
statements can be identified by the use of words such as
"believes," "intends," "estimates," "may," "will," "should,"
"anticipates," "expected" or comparable terminology or by
discussions of strategy. Although the Company believes that the
expectations reflected in such forward-looking statements are
reasonable, it cannot assure that these expectations will prove to
be correct. Such statements involve risks and uncertainties
including those factors identified under the captions "Risk
Factors," "Special Note Regarding Forward Looking Statements" or
"Cautionary Note Regarding Forward Looking Statements" in the
Company's documents filed from time to time with the SEC, including
the Company's Current Report on Form 8-K/A, dated February 11,
2004, and its Annual Report on Form 10-K for the year ending
December 31, 2003 filed with the SEC on March 11, 2004. Should one
or more of these risks materialize (or the consequences of such a
development worsen), or should the underlying assumptions prove
incorrect, actual results could differ materially from those
forecasted or expected. The Company disclaims any intention or
obligation to update publicly or revise such statements whether as
a result of new information, future events or otherwise. For
further information, please contact L. Robert Cohen, Vice
President, Investor Relations of NaPro BioTherapeutics, Inc.,
+1-212-218-8715. DATASOURCE: NaPro BioTherapeutics, Inc. CONTACT:
L. Robert Cohen, Vice President, Investor Relations of NaPro
BioTherapeutics, Inc., +1-212-218-8715; or Investors, Lilian Stern
of Stern Investor Relations, Inc., +1-212-362-1200, or Media, Peter
Steinerman, +1-516-374-3031, both for NaPro BioTherapeutics, Inc.
Web site: http://www.naprobio.com/
Copyright
Napro Biotherapeutics (NASDAQ:NPRO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Napro Biotherapeutics (NASDAQ:NPRO)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Napro Biotherapeutics (MM) (NASDAQ): 0 recent articles
More Napro Biotherapeutics (MM) News Articles